CM-24 is under clinical development by Purple Biotech and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CM-24 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CM-24 is under development for pancreatic cancer, melanoma, ovarian cancer, non-small cell lung cancer, metastatic pancreatic cancer, metastatic adenocarcinoma of the pancreas, pancreatic ductal adenocarcinoma, papillary thyroid cancer, and colorectal cancer. The therapeutic candidate is administered by intravenous route. CM-24 is a humanized immunoglobulin G4 (IgG4) (kappa) isotype immune-modulating monoclonal antibody that binds to CEACAM1, a protein used by cancer cells to suppress the immune system. It was under development for the treatment of metastatic melanoma, bladder and gastric cancer.
Purple Biotech overview
Purple Biotech is a clinical-stage biotechnology company that develops first-in-class medication that helps surmount immune evasion and drug resistance by tumors. Its oncology pipeline includes NT219, CM24, and IM1240. NT219 (a dual inhibitor) is a small molecule for the treatment of solid tumors and is used in an increased dose together with cetuximab to treat recurrent and metastatic squamous cell carcinoma of the neck and head. CM24 is a humanized monoclonal antibody that blocks CEACAM1 (an immune checkpoint protein), which aids tumor immune evasion and survival by tumors through multiple pathways. The company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors for the treatment of pancreatic ductal adenocarcinoma. In collaboration with Bristol Myers Squibb, the company is evaluating the combination of CM24 with the PD-1 inhibitor nivolumab, besides chemotherapy. IM1240 is a preclinical, conditionally-activated tri-specific antibody that engages both NK cells and T cells to demonstrate a robust, localized immune response within the tumor microenvironment. Purple Biotech is headquartered in Rehovot, Israel.
For a complete picture of CM-24’s drug-specific PTSR and LoA scores, buy the report here.